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modifications to these proteins (S-nitrosylation), thereby silencing multiple metabolic processes, including apoptotic cell death regulation (Mannick, 2007) and the inhibition of mitochondrial oxidative phosphorylation during hypoxia or a protection against hypoxia by increasing the binding activity of hypoxia-inducible factor 1. S-nitrosylation of NF-κB can suppress inflammation (Rabelink & Luscher, 2006) . L-arginine depletion occurs when it is diverted into alternative metabolic pathways through the redox induction of enzymes such as arginase and protein methyltransferases. Under prolonged redox signaling, eNOS itself may switch from being an enzyme that produces NO into the one that produces reactive oxygen species. This event is known as NOS "uncoupling", and it is dependent on the lack of availability of the cofactor tetrahydrobiopterine, which is essential for the eNOS-dependent production of NO. The amount of tetrahydrobipterin can be reduced as a result of direct oxidation by ROS derived from another source followed by the amplification of oxidative stress or when hydrogen peroxide induces the inactivation of the enzymes GTP-cyclohydrolase and dihydrofolate reductase, which generate and regenerate tetrahydrobiopterine. When its levels are low the heme group in eNOS will directly yield superoxide and hydrogen peroxide (Crabtree et al., 2009) . The enzyme may reduce molecular oxygen rather than transfer electrons to Larginine, thereby generating superoxide. Superoxide is believed to originate from the oxygenase domain of the enzyme through the dissociation of a ferrous-dioxygen complex that is normally stabilized by tetrahydrobiopterine (Xia et al., 1998) . This uncoupling converts eNOS into an accelerator of redox signaling followed by the production of large amounts of ROS inducing a proinflammatory state (Rabelink & Luscher, 2006) . Several enzymes such as the hemoxygenase system (Ryter et al., 2006) , antioxidant enzymes, thioredoxin reductase and glutathione reductase (Hojo et al., 2002) can scavenge ROS and "fine-tune" this activation cascade, to the extent that ROS exceed the antioxidative capacity of cellular antioxidants (Cai & Harrison, 2000) . This process explains how the chronic activation of the endothelium or impaired activity of eNOS can lead to the endothelial dysfunction. Endothelial iNOS may be induced in both physiological and pathological conditions. Known physiological settings include pregnancy, treatment with oestradiol (Weiner et al 1994) , shear stress, chronic exercise or receptor agonists (such as bradykinine and vascular endothelial growth factor). In activated ECs iNOS can be induced producing much higher levels of NO then those present under physiological conditions and that is implicated in the pathogenesis of a wide variety of diseases involving endothelium (Djordjević et al., 2004; Djordjević et al., 2008) . iNOS is highly regulated by cytokines, some of which promote while others inhibit the enzyme induction. Although there are indices suggesting that a cocktail of three cytokines (TNF-, IL-1 and IFN-) (Steiner et al., 1997) , is neccesery for NOS induction, most data showed that NOS induction can be triggered by a mixture of two cytokines especially IL-1 and TNF (Mantovani et al., 1997) . Transforming growth factor - (TGF-) reduces cytokine-induced iNOS activity by inhibiting iNOS mRNA translation and increasing iNOS protein degradation, while IL-4 interferes with iNOS transcription (Bogdan et al., 1991) . The disruption of genes encoding IFN-, part of its receptor or an IFN regulatory factor results in a phenotypic deficiency in iNOS expression. EC produced NO may exert an autocrine function. It inhibits the cytokine-induced expression of adhesion molecules and cytokine production by ECs through inducing and stabilizing of NF-κB inhibitor (Peng et al., 1995) , thus attenuating proinflammatory responses.
NADPH oxidase
An emerging paradigm in vascular homeostasis involves the balance between ROSmediated and NO-mediated signals. ROS contribute to cellular signaling, affecting almost all aspects of cellular function including gene expression, proliferation, migration and cell death. It is now clear that ROS play an important role in regulating the normal function of the endothelium. However, the generation of ROS both within ECs and in adjacent cells such as vascular smooth muscle cells, adventitial fibroblasts and inflammatory cells has a major role in the genesis of endothelial activation and dysfunction. The potential sources of superoxide in ECs include the mitochondrial electron transport chain, xanthine oxidase, cytochrome p450 enzymes, uncoupled NOS and NADPH oxidases. Mitochondria are both a source and a target for ROS. Because they are susceptible to oxidative damage it can result in enhanced mitochondrial ROS production (Cai & Harrison, 2000) . Xanthine oxidase is expressed on the luminal surface of the endothelium and catalyses the conversion of hypoxanthine into urate in the process that generates superoxide. An increased xanthineoxidase-derived superoxide production is involved in endothelial dysfunction in several diseases. NADPH oxidase is considered as a rather special source of ROS generation since its the primary function is the regulation of ROS production, primarily identified and characterized in phagocytes where it plays an essential role in host defense against microbial organisms. Furthermore it has become apparent that ROS production by NADPH oxidase homologues in non-phagocytic cells also plays an important role in the regulation of signal transduction via the modulation of kinase and phosphatase activities or through gene transcription (Finkel, 2003; Groemping & Rittinger, 2005) . The phagocytic enzyme is normally quiescent, but becomes activated during the neutrophil oxidative burst when it generates large amounts of superoxide (Brandes & Kreuzer, 2005) . The classical phagocytic NADPH oxidase is composed of two subunits, a catalytic subunit gp91 phox (91 kDa glycosylated protein; where phox is phagocyte oxidase), and p22 phox subunit forming a membrane-bound heterodimeric flavo-cytochrome b 558 . For fully enzyme activation a number of cytosolic regulatory subunits are required namely p67 phox , p47 phox , p40 phox and the small GTPase Rac2 which are translocated to and assembled with the membrane cytochrome in a highly regulated process (DeLeo & Quinn, 1996) that involves the post-translational modification of several cytosolic subunits and specific protein-protein binding through tandem SH3 (Src homology) domains. The tight regulation of enzymatic activity is achieved by two mechanisms: the separation of the oxidase subunits into different subcellular locations during the resting state and the modulation of reversible protein-protein and protein-lipid interactions. In the activated enzyme complex, the flavin-containing catalytic subunit functions as an electron transport system which uses NADPH as a donor of electrons that are transferred to molecular oxygen, resulting in the generation of superoxide. Initially, several homologues of the gp91 phox catalytic subunit have been identified, each encoded by separate genes and designated Noxs. These are now seven members: Nox1, Nox2, Nox3, Nox4, Nox5, Duox1 and Duox2. Nox2 contains gp91 phox . It seems that all the Nox homologues may bind to p22 phox in a similar manner to the gp91 phox / p22 phox complex. In the case of Nox1, homologues of p47 phox and p67 phox (NOXO1 and NOXA1) have been found to be important for its activation. On the other side, Nox4 activation does not require either p47 phox and p67 phox (Ray & Shah, 2005) . ECs express all the classical NADPH oxidase subunits. However, there are a few significant differences between phagocytic oxidase and the enzyme in ECs. Firstly, endothelial oxidase continuously generates small amounts of superoxide even in unstimulated cells, but its activity can be augmented by specific agonists. Secondly, a large proportion of the superoxide generated in ECs is intracellular, whereas neutrophil superoxide generation is mainly in the extracellular compartment. The Nox2 oxidase is predominantly located in a perinuclear distribution in association with the cytoskeleton. There are also many fully preassembled ROS generating oxidase complexes which can explain both the continuous low-level superoxide generation in unstimulated endothelium and the intracellular site of ROS production. The Nox4 isoform is expressed in greater amounts in ECs and seems to contribute to the basal constitutive superoxide generation.. Additionally, ECs express the Nox1 enzyme in smaller amounts than the Nox2 isoform. Endothelial NADPH oxidase may be stimulated by a variety of (patho)physiological stimuli: 1. Agonists of G-protein coupled receptors such as angiotensin II and endothelin, 2. Growth factors such as thrombin and vascular endothelial growth factor, 3. Cytokines such as TNF-, 4. Metabolic factors such as increased glucose, insulin, non-esterified fatty acids, advanced glycation end products, 5. Oxidized lipids, 6. Oscillatory shear stress , and 7. Hypoxia/reoxygenation and nutrient deprivation. A major mechanism involved in NADPH oxidase activation is the PKC (protein kinase C)-dependent phosphorylation of the p47 phox regulatory subunit and its translocation to the membrane heterodimer. TNF- induced endothelial oxidase activation downstream phosphorylation of extracellular signal-regulated kinase, involves not only the phosphorylation of p47 phox , but also its binding to TRAF4 (TNF-receptor associated factor 4) (Li et al., 2005) . The other mechanism, occurs via the action of Src, EGF receptor transactivation and the subsequend activation of PI3-kinase which leads to the robust activation of Rac and an enhanced and prolonged oxidase dependent ROS production. The activation of the oxidase by Rac 1 is therapeutically relevant because Rac 1 activation requires its post-translational modification by isoprenylation, a process that is inhibited by -hydroxy-3-methylglutarylCoA reductase inhibitors (statins).
Endothelial cell activation
Generally, ECs are constantly a target for a wide variety of stimuli which can induce an EC response in three different ways: 1) stimulation -a rapid response of resting ECs initiated by agonists such as histamine, 2) activation -a slower protein synthesis-dependent response mostly initiated by inflammatory cytokines, (these two responses are normal EC functions), 3) injury -a process occurring by strong stimuli which can induce either endothelial necrosis or endothelial dysfunction. A large number of distinct pathogens including viruses, bacteria and their products, protozoa, anti-EC antibodies, reactive oxygen species, rickettsiae and toxins can be directly or indirectly involved in EC activation (Figure 1 ). ECs can be also a target for angiogenic signals in neoplasia, and a major target for an immune reaction directed against alloantigens or xenoantigens. Some of them (like viruses) infect ECs, others (viruses, bacteria and their products, anti-EC antibodies) interact with ECs and induce or modify cytokine production. EC activation triggered by inflammatory cytokines (e.g. TNF-, IFN-, IL-1) or growth factors (e.g. angiotensin II) can induce the expression of a functional program related to thrombosis and inflammation. Thus, under stronger insults ECs initially acquire a proinflammatory and procoagulant phenotype. Since the ultimate goal of the activated EC is to survive, it leads the cell to add to the constitutively-expressed protective machinery by initiating the upregulation of a new set of protective genes, including those for A1 and A20 (Bach et al., 1997) .
Fig. 1. Endothelial cell activation
During activation ECs not only develop a characteristic morphology but also synthesize a new surface protein and soluble mediators not present in the resting vascular endothelium. Many of these morphologic and functional changes can be induced in cultured ECs by purified immune mediators, such as monokines, lymphokines and bacterial LPS. Numerous inducible genes involved in endothelial activation, including cell adhesion molecule 1, Eselectin, tissue factor, interleukin-1 (IL-1), interleukin-6 (IL-6), G-CSF, interleukin-8 (IL-8) and c-myc contain elements in their promoter regions that could be recognized by the NF-κB 1/Rel family of transcription factors. ECs also express an inhibitor of NF-κB, IκB-, and can dramaticaly modulate the level of this inhibitor in parallel with the activation process. One of the earliest changes in the endothelium activation is an alteration in the glycocalyx composition. Glycocalyx contains anchoring proteoglycans (CD44, the syndecan protein family) and conecting glycosaminoglycans. The major class of negatively charged polysaccharides that contribute to the glycocalyx include heparan sulfate, chondroitin sulfate and the nonsulfated hyaluronan. The various combinations of possible sulfation modifications within a heparan sulfate chain can give rise to many structurally distinct binding sites for a wide rage of different ligands, including chemokines, growth factors, lipoproteins, lipases, serine protease inhibitors, thrombomodulin, extracellular SOD and complement factors (Weinbaum et al., 2007) . The endothelial glycocalyx (Tarbell & Ebong, 2008) markedly changes its properties under inflammatory conditions which facilitates rolling adhesion and tight adhesion of leucocytes. Cytokines activate proteases either located in glycocalyx or secreted by activated ECs and leucocytes which partially degrade the glycocalyx layer and thereby provide a mechanism for leucocyte recruitment (Mulivor & Lipowsky, 2004) . Also, the release of glycocalyx components into the circulation can be considered as a very early sign of endothelial activation. So, syndecan 1 and heparan sulfates have been shown to be released from the endothelium following stimulation by thrombin or endotoxin (Fitzgerald et al., 2000) , and circulating glycocalyx components have been explored as a measure of endothelial activation in patients with type 2 diabetes and the coronary artery disease (Bruegger et al., 2009; Wang et al., 2009) . During sustained endothelial activation platelets and leucocytes bind to the endothelial surface leading to the formation of proinflammatory factors such as thrombin and the membrane attached complex which can cause further activation of the endothelium and promote the formation of membrane particules so called microparticles. Microparticles from ECs, platelets and leucocytes are released into the circulation. The interaction between ECs and pericytes is disrapted and pericytes begins to produce proteases that damage the endothelial basement membrane. These processes may lead to the apoptosis or necrosis of ECs or ECs can be detached and detected in the circulation (Haubitz & Woywodt, 2004) .
Nuclear factor-κB
NF-κB is a redox sensitive transcription factor associated with rapid-response activation mechanisms. It consists of homo-or heterodimeric complexes of members of the Rel family of proteins: p50/p105 (NF-κB1, derived from its p105 precursor), p52/100 (NF-κB2 and its p100 precursor), p65/RelA, c-Rel and Rel-B. The best characterized form is the heterodimer p50/p65. These proteins share a 300 amino acid region known as the Rel homology domain, which mediates DNA binding and dimerization. In resting cells, NF-κB binding proteins are in an inactive cytosolic form and are complexed to members of a family of inhibitory proteins referred to as IκB (IκB-, IκB-, IκB-, IκB-σ and IκB-ε). IκB- is the best characterized inhibitor, which binds to the p65 subunit of NF-κB (Baldwin, 1996) . All IκB forms contain multiple ankyrin repeats which are involved in interactions with NF-κB. NF-κB can be activated by a number of divers agents such as the citokines, IL-1, and TNF-, LPS, oxidative stress, oxidatively modified LDL particles, viral products, advanced glycosylation end products and physical forces. These stimuli may activate the NF-κB kinase complex through distinct signaling pathways that culminate in the activation of the IκB kinase. In this way they induce IκB- release from the p65 subunit after its phosphorilation. After phosphorilation IκB is ubiquitinated and targeted for degradation via the nonlysosomal ATP-dependent proteosome pathway followed by a rapid loss of this protein. Alterations in IκB- at the levels Ser 32 and Ser 36 , which prevent its phosphorilation and degradation, lead to blocking IκB- ubiquitination and subsequent degradation (Brown et al., 1995) . A removal of IκB- exposes a nuclear localisation sequence in NF-κB which is then able to translocate to the nucleus, bind to a specific DNA sequence (5'-GGGRNNYYCC-3') and activate NF-κB dependent genes. IκB- is rapidly resinthesized after the loss, suggesting an autoregulatory mechanism for NF-κB regulation in the endothelium (Thurberg & Collins, 1998) . When the IκB- pool is replenished, IκB- translocates to the nucleus and displaces the transactivating form of NF-κB from promotor elements. The NF-κB/IκB- complex is then transported back to the cytoplasm in the inactive form. Further, the genes that code for p65, p105 and IκB- are highly inducible in ECs in response to the stimuli that activate NF-κB. The promoter of the IκB--gene contains κB binding sites. p65 stimulates IκB- gene expression (Baldwin, 1996) and p65 stabilises IκB- protein indicating that p65 and IκB- have been directly linked in an autoregulatory loop. The NF-κB/IκB- autoregulatory system may ensure that the induction of NF-κB is transient, and that the activated cell returns to a quiescent state. It allows a continuous maintenance of the cytoplasmatic reservoirs of NF-κB complexes for stimulation in an acute response, and also prepares the EC to return NF-κB to its uninduced condition.
The rapid cytokine-induced activation of NF-κB in ECs is probably similar to that seen in other cell types. However, the recovery kinetics of the NF-κB/IκB- response in the endothelium may be different. The NF-κB remains activated and IκB- levels remain below basal levels for long periods of time than seen in cells programmed for rapid responses, such as macrophages (Read et al., 1994) . It is possible that cytokines released by activated ECs result in an autocrine activation of NF-κB and continued degradation of IκB-. Such prolonged endothelial activation may play a role in recruiting circulating cells to the sites of ongoing inflammatory (artherosclerosis) (Ahn et al., 2006; Brand et al., 1997) or immune processes (autoimmune diseases). The NF-κB activation can be blocked by sodium salicylate and aspirin (Kopp & Ghosh, 1994) . However, in addition to the proinflammatory genes, activated NF-κB may induce a set of protective genes, including antiapoptotic genes that may limit the activation process and thereby regulate the respons to injury. The protective genes include IκB- and hemoxygenase, as well as the antiapoptotic genes A20, Bcl-2, and Bcl-XL. Besides the antiapoptotic activity, the antiapoptotic genes also inhibit the activation of NF-κB in ECs and thus block the induction of the proinflammatory genes (Bach et al., 1997) . Some stimuli, such as laminar shear stress, upregulate genes for manganese superoxide dismutase, cyclooxygenase-2 and endothelial specific nitric oxide synthase. Since this set of genes has antioxidant, antithrombotic and antiadhesive properties, they can be also recognised as "protective". When the protective effect is not adequate, ECs undergo apoptosis. To maintain an antiinflammatory and anticoagulant state the endothelium also requires environmental cues. Laminar shear stress is a key contributor to the integrity of ECs through the inhibition of apoptosis. Shear stress also activates specific transcription factors, such as kruppel-like factor 2 and nuclear factor erythroid 2-related factor 2 (Dekker et al., 2002; Chen et al., 2003) . These transcription factors regulate about 70% of the genes responsive to shear stress, including those that encode typical protective endothelial factors such as eNOS, thrombomodulin and antioxidant enzymes, but at the same time they down regulate genes that encode procoagulant factors such as plasminogen activator inhibitor 1, IL-8 and the tissue factor (Fledderus et al., 2008) . It seems that kruppel-like factor 2 can be directly regulated by shear stress, while the nuclear factor erythroid 2-related factor 2 is released from its inhibitor, kelch-like ECH associated protein 1, through the generation of ROS, which suggests that it functions as a defense mechanism against antioxidants (Kraft et al., 2004) . However, in the stabilisation of the endothelial phenotype a key role belongs to the reciprocal interaction of stromal or epithelial cells with the endothelium. ECs have direct physical contact with pericytes and vascular smooth muscle cells through myoendothelial junctions. Pericytes send signals to the endothelium through number of factors including hydrogen sulfide, all isoforms of VEGF (vascular endothelial growth factor), sphingosine-1-phosphate, platelet-derived growth factor, basic fibroblast growth factor and angiopoietin I (Gaengel et al., 2009; Diaz-Flores et al., 2009 ). Angiopoietin I is best known to stabilize the endothelium and to maintain its quiescent state. If the signaling between angiopoietin I and the ECs is interrupted ECs sprout and migrate; this results in neoangiogenesis (Chen & Stinnett, 2008) .
Regulation of NF-κB dependent gene expression
The activation of the pleiotropic mediator NF-κB in ECs could coordinate the expression of numerous endothelial products which are important in endothelial activation including some cell surface adhesion proteins, cytokines, growth factors, NADPH oxidase, NOS, prostanoides, acute phase reactants and components of the coagulation system. They may be multiple phosphorylation events which play a key role in NF-κB activation. Some of the cytosolic NF-κB/IκB- is associated with the catalitic subunit of the cAMP-dependent protein kinase, PKAc, in an inactive state. The signal-induced degradation of IκB- leads to the activation of PKAc which phosphorilates the p65 subunit of NF-κB on Ser 276 . This causes a conformational change which unmasks the CREB binding protein (cAMP-responsive binding protein) interacting domain on p65. Once CREB interacting domain on p65 is unmasked, NF-κB interaction with a coactivator is enhanced and NF-κB can enter the nucleus (Zhong et al., 1997) . Lysophosphatidylcholine, one of the active molecules present in oxLDL, has been shown to activate NF-κB in primary cultured ECs via a PKC dependent pathway. ECs can also be shown to be responsive to oxLDL in vivo. When unmodified human LDL particles are injected into a rat model, they are localized in the arterial wall were they undergo oxidative modification which is accompanied by an increase in endothelial NF-κB activation and expression of NF-κB dependent genes (Calara et al., 1998) . In the nucleus, the p65 subunit can be phosphoregulated by the components of the p38 and ERK MAP kinase signal patways (Berghe et al., 1998) .
Endothelial cells and inflammation
ECs actively participate in the inflammatory process acting as both a target and a responder to a variety of stimuli. Whatever the initial stimuli (mechanical, chemical, infectious or immunological) they activate ECs. There are two stages of EC activation; the first-EC activation type I which does not require de novo protein synthesis or gene upregulation, occurs rapidly and it is followed by the retraction of ECs, expression of P selectin and release of von Willebrand factor. The second response, EC activation type II, requires time for the stimulating agent to cause an effect via gene transcription and protein synthesis. A stimulating agent acting on the EC surface causes the expression of many genes via the activation of NF-κB (Baldwin, 1996) . EC activation is a graded rather than an all response. For example, changes in EC integrity range from simple increases in local permeability to major EC contraction, exposing large areas of subendothelium. Activation may proceed as an acute response or as a chronic EC activation such as in atherosclerosis and in vascular diabetic complications. Ligands of RAGE (the receptor for advanced glycation end products) mediate continuous NF-κB activation which results in persistent endothelial tissue factor induction. The activation may occur locally, as in transplant rejection, or systematically, as in septicaemia and the systemic inflammatory response. Generaly, EC activation is associated with five core changes including the loss of vascular integrity, expression of leucocyte adhesion molecules, change in phenotype from antithrombotic to prothrombotic, cytokine production and upregulation of HLA molecules. The loss of vascular integrity can expose subendothelium and cause the efflux of fluids from the intravascular space. The first step in EC activation, independently on the initial stimuli, involves inflammatory cytokines mostly TNF-, IL-1 and IFN- (Steiner et al., 1997) . They stimulate ECs to produce monocyte chemotactic protein-1 (MCP-1). Vascular cells produce three more chemokines including IP-10, MIG, I-TAC, when exposed to the inflammatory mediator IFN-, a molecule produced by activated T cells and perheps macrophages. MCP-1 recruits and activates immune and inflammatory cells which produce inflammatory cytokines and induce the expression of adhesion molecules. The upregulation of surface glycoproteins such as endothelial leucocyte adhesion molecule-1 (ELAM-1, also known as E-selectin), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and MHC molecules allows leucocytes to adhere to the endothelium and then move into tissues.
Fig. 2. Endothelial cells and inflammation
Tissue infiltration by circulating leucocytes is a four-step process involving low affinity attachment, roling on the endothelium, high affinity attachment to the endothelium, followed by transmigration across the ECs lining blood vessel walls. These processes are mediated by adhesion molecules. Four distinct families of adhesion molecules including cadherins, immunoglobulin superfamily members, selectins and integrins are involved in vascular cell-cell adhesion. These molecules are requred four: 1. The formation of the junctional complexes that enable the assembly of ECs into functional vascular networks; 2. They mediate the leucocyte-endothelial adhesive interactions involved in the trafficking of leucocytes out of the circulation but the set of adhesion molecules expressed by ECs depends on the stimuli (Cook-Mills & Deem, 2005) while the specificity of the adhesion molecules regulates the specificity of leucocyte homing to tissues; and 3. They contribute to contacts between pericytes and the endothelium that are important to the regulation of EC proliferation, addressin interaction, rolling which can also be mediated by the interaction of leucocyte 41-integrin and VCAM-1/CD106. A transitory contact of leucocytes with the endothelium or their rolling are mediated by low-affinity receptors, selectins and addressins. The binding of selectins on leucocytes stimulates "outside-in" signals in leucocytes, increasing the affinity of the integrin family of receptors, which then bind to EC adhesion molecules such as ICAM-1/CD54 and VCAM-1. The regulation of the expression of the adhesion molecules occurs by negative control as well as at the level of gene transcription. For example, NO can reduce leucocyte adhesion to arteries and can counteract the induction of VCAM-1 expression by ECs stimulated by inflammatory cytokines such as IL-1 or TNF-. At the transcriptional level, NO inhibits VCAM-1 gene expression in ECs by interfering with the NF-κB signaling pathway via a non-cyclic GMP-mediated mechanism (Peng et al., 1995) . Instead, NO inhibits NF-κB by inducing its inhibitor IκB-. Thus, NO acts as an anti-inflammatory mediator. Leucocyte integrin affinity is also rapidly increased by "inside-out" signals from leucocyte chemokine receptors triggered by chemokines expressed on the surface of ECs. When leucocyte integrin affinity is increased, leucocyte roling is arrested.
More sustained sticking of leucocyte to the endothelium is mediated by VCAM-1 which binds to the cognate ligand VLA-4 (very late adhesion molecule-4) that is expressed by the very types of leucocytes recruited to the intima: monocytes and lymphocytes, respectively. Once adherent, the leucocytes enter the vascular wall. Leucocyte migration from the blood into tissues is vital for immune surveillance and inflammation. Leucocytes can stimulate "outside-in" signal transduction in ECs and some of these signals can cause localized alterations in EC junctions. At the sites of inflammation, activated antigen specific lymphocytes are the first to migrate across activated endothelium expressing adhesiom molecules. During the leucocyte-EC interaction, the EC promotes the migration of leucocytes or removes leucocytes that are in the early stages of apoptosis. Leucocytes can be found within the vacuolar structures of ECs only when ECs phagocytose apoptotic leucocytes. This function of ECs may be a mechanism by which the endothelium is protected from the localised vascular damage which would occur if apoptotic leucocytes were to undergo necrosis. Thus, we can say that ECs modulate leucocyte migration by promoting leucocyte migration or removing leucocytes undergoing apoptosis. While lymphocytes migrate acros activated endothelium neutrophils and monocytes migrate between ECs (Mamdouh et al., 2003) . It has been shown that neutrophils roll across the luminal surface of human umbilical vein ECs to bicellular and tricellular EC junctions. In response to peptid N-formyl-methionyl-leucyl-phenylalanine neutrophils migrate through a pore in nonactivated cutaneous ECs. Adhesion molecule signals result in alterations in the function of cell junction proteins and/or contractile forces in the EC, thereby opening an EC junction and permitting leucocyte migration into the tissue. During neutrophil and monocyte migration, localized EC retraction of lateral junctions occurs at the site of leucocyte migration showing that contractile forces in ECs have an active role in leucocyte migration.
Selectins
Three selectins have been characterized and named according to their cell of original discovery: P-selectin (platelet selectin), E-selectin (EC selectin) and L-selectin (leucocyte selectin). These are glycosylated proteins, which share several structural features and support leukocyte-EC and leukocyte-platelet adhesion. L-selectin is constitutively expressed by most leucocytes, but not by other cell-types. The ECs of high endothelial venules of lymph nodes constitutively express ligand for L-selectin (lymphocyte homing receptors) and L-selectin plays a central role in the normal recirculation of lymphocytes. ECs from other vascular beds also support L-selectin-mediated adhesion after the exposure to cytokines. P-selectin, which is expressed by ECs and platelets, is stored in intracellular granules and mobilized to the surface upon cell activation where it supports the adhesion of granulocytes, monocytes and some lymphocyte subsets. E-selectin is expressed by cytokine-activated ECs and supports adhesion of granulocytes, monocytes, some memory T-lymphocytes and natural killer cells (Bevilacqua & Nelson, 1993; Brady, 1994) .
Integrins
Selectin -mediated adhesion facilitates the immobilization of phagocytes by the interaction of phagocyte integrins with immunoglobulin-like molecules on the endothelium. Integrins are heterodimeric glycoproteins composed of non-covalently associated  and  subunits. Integrins mediate diverse cell-cell and cell-matrix interactions. The most important integrins in leukocyte-endothelial adhesion include the very late activation antigen-4 1 integrin (VLA-4) and the CD11/CD18 -2 integrins. VLA-4 is constitutively expressed by lymphocytes, monocytes, basophiles and eosinophils, but not neutrophils. This protein is a ligand for the inducible vascular cell adhesion molecule-1 (VCAM-1) and also mediates cell attachment to fibronectin and possibly other matrix components. -2 integrins include three well characterized members: CD11a/CD18 (LFA-1, Lymphocyte function-associated antigen-1), CD11b/CD18 (Mac-1) and CD11c/CD18 where CD11 and CD18 are the  and  subunits, respectively. LFA-1 is found on all T-cells and also on B-cells, macrophages and neutrophils. CD11 subunits are encoded by distinct genes in a cluster on chromosome 16, while CD18 is encoded by a single gene on chromosome 21. CD18 contains a short cytoplasmic tail which has several potential phosphoregulation sites, a highly conserved transmembrane domain and a long extracellular region which contains a conserved cysteinrich region that is necessary for surface expression (Brady, 1994) . The major ligands for CD11a/CD18 are the intercellular adhesion molecules-1 and 2 (ICAM-1 and ICAM-2). ICAM-1 is also a ligand for CD11b/CD18 which supports phagocyte adhesion to cellular and acellular substrates by ICAM-1 independent mechanisms. Other ligands for CD11b/CD18 include fibrinogen, clotting factors and complement fragments (C3bi).
Immunoglobulin-like molecules 4.3.1 Platelet-EC adhesion molecule-1 (PECAM-1)
PECAM-1 adhesion at the lateral borders of nonactivated ECs participates in the formation of EC junctions and my be a critical regulator of phagocyte diapedesis between ECs. PECAM-1 also mediates the binding with PECAM-1 on leucocytes. Although there is PECAM-1 independent models of lymphocyte, neutrophil and monocyte migration anti-PECAM-1 antibodies can block monocyte diapedesis across TNF-α or IL-1-activated ECs (Schenkel et al., 2002) . PECAM-1 can activate signals that increase leukocyte adhesion (Chiba et al., 1999) . Also, PECAM-1 has been shown to recycle between the cell membrane and a cytoplasmic compartment juxtaposed to the membrane. PECAM-1 is recruited to the EC surface at the sites of monocyte transmigration (Mamdouh et al., 2003) . A treatment of nonactivated cells with an inducer of oxidative stress increases PECAM-1 phosphorylation followed by an increase in leukocyte migration. PECAM-1 phosphorylation is regulated by ser/thr phosphatases which can be blocked with anti-PECAM-1 antibodies, antioxidants or inhibitors of PKC, Ras and glutathione synthesis (Rattan et al., 1997) . The homophilic adhesion of PECAM-1 stimulates its binding to several intracellular proteins involved in signaling including Src homology containing phosphatase, phospholipase C- and Pi-3k (Jackson et al., 1997; Pellegatta et al., 1998; Pumphrey et al., 1999) . Phosphorylated PECAM-1 can be linked to the cytoskeletal catenins thereby limiting their translocation to the nucleus thus modulating gene expression. PECAM-1 localization in ECs is modulated by cytokines. The simultaneous treatment with TNF-α and IFN- moves PECAM-1 out of lateral junctions without inhibiting the ability of monocytes to migrate across these ECs under laminar flow conditions suggesting that sufficient PECAM-1 is still available for migration (Shaw et al., 2001 ).
Intercellular adhesion molecule-1 (ICAM-1)
ICAM-1 is a glycoprotein which contains five tandem immunoglobulin domains. It is constituvely expressed on many cell types but can be increased on endothelium by inflammatory mediators (Roebuck & Finnegan, 1999) . The first and third immunoglobulinlike domain of ICAM-1 bind to the counter-receptors of LFA-1 and membrane-activated complex-1 (CD11b/CD18) respectively, on leucocytes, but it can also bind to fibrinogen on lymphocytes (Dupperay et al., 1997) . A chelation of intracellular calcium or the inhibition of PKC in IFN- treated brain EC lines blocks ICAM-1 dependent lymphocyte migration without affecting lymphocyte adhesion (Etienne-Manneville et al., 2000) . ICAM-1 stimulates ECs to produce chemokines through the activation of ERK1 and ERK2 (Sano et al., 1998) suggesting that ICAM-1 induces EC signals that are required for lymphocyte migration. ICAM-1 signals can also regulate the EC actin cytoskeletion. The antibody cross-linking of ICAM-1 on TNF-α-activated pulmonary microvascular ECs activates xanthine oxidase and p38 MAPK (Wang & Doerschuk, 2001) , resulting in actin rearrangement, and can also induce phosphorylation of another cytoskeleton protein ezrin. ICAM-1 associates with the cytoskeletal protein ezrin through phosphatidylinositol 4,5-biphosphate (Heiska et al., 1998) . Homotypic and heterotypic lymphocyte adhesion mediated by the interaction of ICAM-1 and CD11a/CD18 facilitates other important lymphocyte functions including antigen recognition, lymphocyte co-stimulation and cytotoxicity.
Vascular cell adhesion molecule-1 (VCAM-1)
VCAM-1 is a glycoprotein containing seven immunoglobulin-like domains which predominates in ECs. A second form of VCAM-1, consisting of six immunoglobulin-like domains, is produced in some tissues by alternate splicing. VCAM-1 is constitutively expressed at low levels by ECs and can be induced on these and other cell-types by cytokines. VCAM-1 supports the adhesion of eosinophils, basophils, monocytes and lymphocytes but not neutrophils, through the interaction with VLA-4. The binding of lymphocytes to VCAM-1 stimulates localized EC-shape changes and the "opening of a narrow passage way" through which leucocytes can migrate (Cook-Mills & Deem, 2005; Matheny et al., 2000) . Lymphocyte binding to VCAM-1 activates ECs NADPH oxidase for the generation of ROS in ECs which constitutively express VCAM-1 and the MCP-1. The VCAM-1-mediated activation of NADPH oxidase is dependent on calcium flux and the small molecular weight G protein Rac1. Rac1 is involved in the assembly of the active NAPH oxidase complex in ECs such as in neutrophils (Dorseuil et al., 1995) . ICAM-1 and PECAM-1 do not activate EC NADPH oxidase. The VCAM-1-stimulated EC NADPH oxidase activity is required for VCAM-1-dependent lymphocyte migration because the inhibition of EC NADPH oxidase blocks MCP-1 stimulated, VCAM-1 dependent lymphocyte migration without altering lymphocyte adhesion. ROS scavengers inhibit VCAM-1 dependent lymphocyte migration while VCAM-1 dependent lymphocyte migration is not blocked by the inhibition of ROS-generating enzymes NOS, xanthine oxidase or cytochrome p450 on ECs (Matheny et al., 2000) . Lymphocyte binding to VCAM-1 induces a low concentration of hydrogen peroxide (1mol) production in ECs (Tudor et al., 2001 ) much lower than those (50-200 mol) produced by neutrophils and macrophages for the destruction of pathogens (DeLeo & Quinn, 1996) or released in some diseases (Thannickal & Fanburg, 2000) . Low levels of ROS induce rapid, transient and reversible signals. This is important, since once a leucocytes reach an EC junction, the process of transmigration occurs within a couple of minutes. Another function of the ROS produced during VCAM-1-dependent lymphocyte migration is the activation (within minutes) of matrix metalloproteinases (MMPs) associated with ECs or IL-4 activated ones. The EC-derived hydrogen peroxide also activates lymphocyte-associated MMPs but 2-5 hours later. These results show that the ECs-associated rather than the lymphocyteassociated MMPs are required for VCAM-1-dependent lymphocyte migration across VCAM-1-expressing ECs (Deem & Cook-Mills, 2004) . Hydrogen peroxide produced by VCAM-1 stimulation has a direct, rapid effect on ECassociated MMPs. ROS activate purified MMPs by oxidizing the cysteine in the propeptide arm opening the arm and exposing the MMP active site (Murphy et al., 1994) which stimulate the autocatalytic removal of the arm, forming an active MMP (Van Wart & BirkedalHansen, 1990 ). Contrary to EC-associated MMPs, hydrogen peroxide indirectly activates lymphocyte-associated MMPs through the down-regulation of the expression of the high levels of tissue inhibitors of MMPs (TIMPs) on lymphocytes (Deem & Cook-Mills, 2004) which takes several hours indicating that lymphocyte MMPs are likely involved in the leukocyte migration through the extravascular tissue (Cook-Mills & Deem, 2005) . MMPs associated with ECs are more important than secreted MMPs during lymphocyte migration. Among MMPs the EC-associated MMP-2 and MMP-9 are likely to degrade matrix and EC junction molecules at the site of transmigration (Herren et al., 1998) .
Endothelial cells and vasculitis

Vasculitis triggered by infectious agents
Vasculitis can be a primary disease, that is not associated with another cause. Or, it may be a complication of some other diseases such as infections, malignancy, reactions to certain medications (Zhang et al., 2010) , a complication after an organ transplant, a connective tissue disease or other causes. The participation of ECs in the pathogenesis of vascular inflammation is complex. On one hand, the vascular endothelium may be the target for injury. On the other hand, ECs may actively participate in amplifying and maintaining the inflammatory process. The role of ECs seems to be more prominent in small vessel vasculitis, such as hypersensitivity vasculitis and vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA). In larger vessel vasculitis, ECs are the crucial protagonist of the vascular response to inflammation which leads to the amplification of the inflammatory response, vessel remodeling and repair, and eventually, vessel occlusion, which is the source of some of the most severe complications in patients with systemic vasculitis. Although most of the infection related vasculitides are immune-complex-mediated (hepatitis B virus-related polyarteritis nodosa, and hepatitis C virus associated cryoglobulinemia) some pathogens are able to directly infect the ECs. Primary vasculitis can be induced by several pathogenic mechanisms. The direct infection of ECs include: bacterial vasculitis (naisserial), spirochetal vasculitis (syphilitic), mycobacterial vasculitis (tuberculous), rickettsial vasculitis (Rocky Mountain spotted fever), fungal vasculitis (aspergillosis) and viral vasculitis (herpes virus, herpes zoster) (Heeringa et al., 2004) . Rickettsiae and herpes virus family members, particularly cytomegalovirus are the best documented (Mandell & Calabrese, 1998) . Serious infections by these agents frequently include vasculitis lesions. The proliferation of the rickettsial organism in small-vessel walls elicits an inflammatory response that results in focal vascular inflammation, often with necrosis and hemorrhage. However most forms of vasculitis do not appear to be caused by the direct infection of vessel walls by pathogens.
Immune complex-mediated vasculitis
Noninfection immunologic mechanisms that cause vasculitis include cell-mediated inflammation, immune complex-mediated inflammation and inflammation induced by ANCA. Immune complex-mediated vasculitis include: cryoglobulinemic vasculitis, HenochSchonlein purpura, serum sickness vasculitis, lupus vasculitis, infection-induced immune complex vasculitis (hepatitis virus), some drug-induced vasculitis (sulfonamide-induced vasculitis), some paraneoplastic vasculitis, and Goodpasture's syndrome (mediated by anti GMB antibodies) (Heeringa at al., 2004) . In immune complex-mediated vasculitis, EC morphology is altered and the luminal endothelium may be destroyed. Complement-mediated lysis as well as neutrophil-mediated EC damage are the main mechanisms of endothelium cell injury in these processes (Cid, 2002) . The membrane attack complex C5b-9, final product of the complement activation cascade, has been detected in the necrotizing vasculitis of the polyarteritis nodose type (Kissel et al., 1989) .
ANCA-mediated vasculitis
Wegener's granulomatosis, microscopic polyangitis, and Churg-Strauss syndrome are the major forms of small-vessel vasculitis that are strongly associated with ANCA (Heeringa et al., 2004) . ANCA vasculitis may be induced by some drugs, such as thiouracil. There are two clinically important forms: cytoplasmatic ANCA (cANCA) and perinuclear ANCA (pANCA). ANCA are autoantibodies that are directed against constituents of the primary granules of neutrophils and the peroxidase positive lysosomes of monocytes. The primary antigenic targets for ANCA are proteinase-3 (PR3), a 29kD neutral serin protease, and myeloperoxidase (MPO), a 140kD enzyme involved in the generation of ROS (Falk & Jennette, 1988; Jennette et al., 1990) . ANCA recognizes MPO or PR3 translocated to the neutrophil membrane on TNF-α or interleukin-8 (IL-8) primed neutrophils (Flint et al., 2010) or may bind to Fc receptors through their Fc portion. Both interactions, specific and Fcmediated appear to be functionally relevant Porges et al., 1994) . ANCA immunoglobulin G can activate neutrophils and monocytes. ANCA binding to neutrophils may stimulate or amplify many neutrophil functions including respiratory bursts which generate ROS, degranulation and protease release , NO production (Tse et al., 2001) , and chemotactic activity. ANCA binding also stimulates integrin expression and integrin-mediated homotypic adhesion and adhesion to ECs (Radford et al., 2000) . Homotypic interactions mediated by neutrophil integrins are required for enhanced TNF-α induced neutrophil activation by ANCA. ANCA-stimulated neutrophil function results in an augmentation of neutrophil-mediated EC injury by inducing EC detachment and lyse of ECs previously damaged by other mediators. Further, in an inflammatory microenvironment, enzymes released by activated neutrophils, including MPO and PR3, may induce EC apoptosis (Yang et al., 2001 ). ANCA-mediated monocyte and neutrophil activation has also been shown to induce the expression and secretion of proinflammatory cytokines (IL-1, IL-6, IL-8, TNF-α), chemokines (MCP-1) and prostanoids (Cid, 2002; Cid et al., 2004) . Such mediators may contribute to the amplification and propagation of the inflammatory process. The detection of ANCA is an important diagnostic and prognostic marker. Testing of ANCA is indicated in patients with evidence for the ANCA disease such as severe pulmonary hemorrhage, especially if accompanied by evidence for glomerulonephritis, peripheral neuropathy, purpura, hemorrhagic sinusitis or other manifestations of small-vessel vasculitis. However, the use of ANCA as a marker of the disease and its activity show a number of limitations such as the occurrence of high ANCA titers with no disease activity, or ANCA presence in non-vasculitis disorders, such as endocarditis (Choi et al., 2000) or tuberculosis (Flores-Suarez et al., 2003) . In addition, circulating ECs have been used as markers in a variety of vascular disorders (Dignat-George & Sampol, 2000) and also their use is demonstrated in ANCA-associated small-vessel vasculitis (Haubitz and Woywodt, 2004) . Recently it has been documented that an increase risk for relapse appears to be related to the presence of anti-PR3 antibody seropositivity.
Anti endothelial cell antibodies
Circulating anti-EC antibodies have been detected in several vasculitides including Wegener's granulomatosis, microscopic polyangitis, Kawasaki diseases, thromboangiitis obliterans, Bechet's disease and Takayasu's arthritis (Praprotnik et al., 2001) . It seems that a large, highly heterogeneous group of antigens can be recognized by anti-EC antibodies. Some anti-endothelial antibodies, such as those detected in Kawasaki disease, recognize cytokine-inducible molecules, while others, such as those detected in Wagener's granulomatosis and microscopic polyangitis, recognize constitutive EC antigens (Del Papa et al., 1996) . Studies in vitro have shown that some anti-EC antibodies may trigger complement activation or anti-body-dependent cellular cytotoxicity. These mechanisms might contribute to EC damage in systemic vasculitis. That alloantigens can activate ECs is well recognized within transplantation where HLA-specific antibodies can activate EC NF-κB (Savage & Williams, 2007; Smith et al., 2000) . EC antibodies arise most probably as a secondary event to endothelial injury. Initial endothelial injury may result from pathogenic processes that may be unleashed during the development of the vasculitis process itself (for example, by proteolytic enzymes released from neutrophils after their inappropriate activation by ANCA). It is also likely that sequestered viral infections, such as cytomegalo-virus that can replicate within ECs, may become relatively more activated during the development of an autoimmune response and particularly after the introduction of immnosuppression. That cytomegalovirus can induce anti-EC antibodies is recognized (Toyoda et al., 1999) . The binding of anti-EC antibodies to EC in vitro elicits a calcium-flux, the secretion of the chemokines MCP-1 and GCP-2 (but not IL-8 or GRO-), and the upregulation of the ligands MHCclass I related antigen A (MICA) and vascular adhesion protein-1 (VAP-1). Signal transduction via the SAPK/JNK pathway appears to be important in the increased expression of MCP-1, GCP-2 and MICA. In addition, anti-EC antibodies also activate NF-κB. However, it has been demonstrated that anti-EC antibodies have an ability to induce EC apoptosis via the recognition of Hsp60 (Jamin et al., 2005) . Once present, anti EC antibodies have the potential to inhibit potent antiinflammatory mechanisms (Nara et al., 2006) .
The endothelial cell as an inflammation amplifier
ECs are able to amplify the inflammatory response by three main mechanisms: adhesion molecule expression, cytokine production and angiogenesis. Most of the primary immunopathogenic mechanisms playing a role in the pathogenesis of blood vessel inflammation in vasculitis include adhesion molecule expression and function . The studies in vitro show that complement activation products induce adhesion molecule expression by cultured ECs. C1q induces E-selectin, ICAM-1 and VCAM-1 (Del Papa et al., 1996) and C5a can upregulate P-selectin expression (Foreman et al., 1994) . Immune complex and complement-mediated vessel damage in vivo require adhesion molecule expression and function. Also, ANCA binding to EC membrane-associated PR3 or related epitopes may induce Eselectin and VCAM-1 expression by ECs. PR3 released by neutrophils in the vicinity of ECs may induce EC ICAM-1 expression. Anti-EC antibody binding to ECs also induces endothelial adhesion molecule expression (Cid, 2002) . The main inducers of endothelial adhesion molecules are the cytokines IL-1, TNF- and IFN- which are produced by activated lymphocytes and macrophages in an vasculitis area (Raines & Ferri, 2005) . The expression of inducible adhesion molecules E-selectin and VCAM-1 by ECs as well as the upregulated constitutive expression of ICAM-1 were detected in patients with cutaneous leucocytoclastic vasculitis, Kawasaki disease, classical polyarteritis nodosa and gian-cell arteritis (Cid et al., 2000) . In Wegener's granulomatosis, microscopic polyangitis and ANCA associated glomerulonephritis VCAM-1 and ICAM-1 expression were observed at the glomerular tuft as well as in tubular epithelial cells and peritubular capillaries (Rastaldi et al., 1996) . In small vessel vasculitis, endothelial adhesion molecule expression occurs in luminal endothelium (Sais et al., 1997) . In medium-sized vasculitis, the luminal endothelium only expresses constitutive or inducible adhesion molecules at early stages. As the inflammatory process proceeds, the luminal endothelium is damaged and the vascular lumen is occluded. Then, endothelial adhesion molecules are expressed by adventitial neovessels (Coll-Vinent et al., 1998) . In sclerotic glomeruli of kidney ANCA-associated vasculitis glomerular expression of ICAM-1 and VCAM-1 declines (Patey et al., 1996) . In large-vessel vasculitis, adhesion molecule expression occurs in neovessels at the adventitia and at the intima/media junction. These observations suggest that infiltrating leucocytes penetrate the vessel wall through the adventitial vasa vasorum and neovessels in large-and medium-sized vessels. In an inflammatory setting ECs have the potential to produce a variety of cytokines, chemokines and growth factors. In vasculitides a stimulation of ECs arises by ANCA binding, some anti-EC antibodies and cytokines released by infiltrating cells. By IL-1 and IL-6 production ECs contribute to the systemic acute phase in many systemic vasculitides. Colony-stimulating factors produced by ECs prolong the half-life of infiltrating leucocytes, while chemokines (IL-8, RANTES, Gro and SLC) selectively attract leucocyte subpopulations which bear specific receptors contributing to tissue targeting and amplifying vessel inflammation.
Conclusion
The endothelium has long been considered a passive physical barrier that only separates blood from tissues. Currently, it is clear that the endothelium is one of the most active organs which regulates many physiological functions and helps to coordinate functions of differentiated tissues in a way that meets the requirements of the organism as a whole. It has also emerged that ECs are the key immuno-reactive cells involved in host defence and inflammation. These cells both produce and react to a wide variety of mediators including cytokines, growth factors, adhesion molecules, vasoactive substances and chemokines, with effects on various cells. Prolonged or exaggerated endothelial activation leads to dysfunction (an early predclinical event of vascular disease) that is regulated by stromal cells and that can drive the vasculitis process with leucocyte recruitment, thrombosis and platelet plugging. Such local vascular inflammation has distant effects on the vascular endothelium leading to systemic endothelial dysfunction. Besides a whole panel of inflammatory markers used to monitor disease activity in systemic vasculitis circulating endothelial cells seem to be a promising new marker of this systemic disorder.
